MV-003 Dysbiosis

Indicaton

Dysbiosis

ApyraMed promotes microbiome recovery and selection of beneficial bacteria after antibiotic treatment. This results in powerful control of antibiotic-induced enteric infections and metabolic alterations.

Therapeutic indications

Type of product

Other biologics

Table

Phase

Discovery
Partnering status

Not partnered
Available in

World-Wide

You may also be interested in

Fosmanogepix

Fosmanogepix is a novel-class i.v. and oral antifungal with activity against yeasts and molds.

Phase III started

Zevtera / Mabelio (ceftobiprole)

Hospital- and community-acquired pneumonia

Marketed

Zevtera / Mabelio (ceftobiprole)

Acute bacterial skin and skin structure infections (ABSSSI)

Marketed